FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:1312-1314 October 2, 2003 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Klugman, K. P. PubMed Citation

Despite the fact that a licensed pneumococcal capsular polysaccharide vaccine has been available for more than 30 years, Streptococcus pneumoniae continues to sicken and kill children and adults throughout the world each day. Pneumococcus-related illnesses including bacteremia, meningitis, and pneumonia affect both industrialized countries (see Figure) and developing countries. However, in developing countries the existence of a much larger burden of death from acute respiratory tract infection adds greater urgency to the situation. Although the polysaccharide vaccine was recently shown in the Journal¹ to have an efficacy of 44 percent for the prevention of bacteremic disease in older adults, . . . [Full Text of this Article]

Source Information

From the Departments of Pediatrics (K.M.E.) and Preventive Medicine (M.R.G.), Vanderbilt University School of Medicine, Nashville.

This article has been cited by other articles:

• Tian, H., Groner, A., Boes, M., Pirofski, L.-a. (2007). Pneumococcal Capsular Polysaccharide Vaccine-Mediated Protection against Serotype 3 Streptococcus pneumoniae in Immunodeficient Mice. Infect. Immun. 75: 1643-1650 [Abstract] [Full Text]